6-mercaptopurine (NSC-755) given intravenously at weekly intervals to patients with advanced cancer.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D006801:Humans; D007275:Injections, Intravenous; D015122:Mercaptopurine / Q000008:administration & dosage* / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D015122:Mercaptopurine